AbbVie’s Head of Digital Science, Michelle Crouthamel, joins Mobile Technologies in Clinical Trials to discuss how AbbVie has implemented digital health technologies to digitize measurements that can improve existing endpoints, uncover new endpoints and reduce the burden on patients by eliminating the need to travel to sleep labs. Key topics include:

Early patient engagement to identify what is meaningful to them
How mobile technologies were implemented into a clinical study and the impact
Navigating regulatory acceptance of digital tools for NDE implementation in a clinical trial

Speakers:

Michelle Crouthamel, Head, Digital Science, Abbvie
Antoniu Fantana, PhD, Lead, Emerging Technology Strategy, Clinical Design, Delivery & Analytics, Eli Lilly

Leveraging Mobile Technologies in the Development of Novel Digital Endpoints

Share

Embed